This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2016 Jun;39(6):396-8.

doi: 10.1038/hr.2016.1. Epub 2016 Jan 28.

Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes

Kouichi Tamura¹, Hiromichi Wakui¹, Kengo Azushima¹, Kazushi Uneda¹, Satoshi Umemura¹

Affiliations

PMID: 26818654
DOI: 10.1038/hr.2016.1

Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes

Kouichi Tamura et al. Hypertens Res. 2016 Jun.

. 2016 Jun;39(6):396-8.

doi: 10.1038/hr.2016.1. Epub 2016 Jan 28.

Authors

Kouichi Tamura¹, Hiromichi Wakui¹, Kengo Azushima¹, Kazushi Uneda¹, Satoshi Umemura¹

Affiliation

¹ Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

PMID: 26818654
DOI: 10.1038/hr.2016.1

No abstract available

PubMed Disclaimer

Similar articles

Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.
Rahman A, Hitomi H, Nishiyama A. Rahman A, et al. Hypertens Res. 2017 Jun;40(6):535-540. doi: 10.1038/hr.2016.193. Epub 2017 Jan 19. Hypertens Res. 2017. PMID: 28100918 Review.
Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.
[No authors listed] [No authors listed] Nat Rev Drug Discov. 2010 Mar;9(3):182. doi: 10.1038/nrd3127. Nat Rev Drug Discov. 2010. PMID: 20190779 Clinical Trial. No abstract available.
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Heerspink HJ, et al. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. Circulation. 2016. PMID: 27470878 Review.
Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.
Pfister M, Whaley JM, Zhang L, List JF. Pfister M, et al. Clin Pharmacol Ther. 2011 Apr;89(4):621-5. doi: 10.1038/clpt.2011.16. Epub 2011 Feb 23. Clin Pharmacol Ther. 2011. PMID: 21346749 Review. No abstract available.
SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA. Jabbour SA. Postgrad Med. 2014 Jan;126(1):111-7. doi: 10.3810/pgm.2014.01.2731. Postgrad Med. 2014. PMID: 24393758 Review.

See all similar articles

Cited by

Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats.
Yoshikawa T, Kishi T, Shinohara K, Takesue K, Shibata R, Sonoda N, Inoguchi T, Sunagawa K, Tsutsui H, Hirooka Y. Yoshikawa T, et al. Hypertens Res. 2017 Jul;40(7):646-651. doi: 10.1038/hr.2017.14. Epub 2017 Feb 16. Hypertens Res. 2017. PMID: 28202943
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.
Scheen AJ. Scheen AJ. Curr Cardiol Rep. 2019 Jun 21;21(8):70. doi: 10.1007/s11886-019-1165-1. Curr Cardiol Rep. 2019. PMID: 31227915 Review.
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R, Marfella R, Docimo G, Lettieri M, Sardu C, Sasso FC. Salvatore T, et al. Int J Mol Sci. 2022 Mar 26;23(7):3651. doi: 10.3390/ijms23073651. Int J Mol Sci. 2022. PMID: 35409011 Free PMC article. Review.
Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.
Rahman A, Hitomi H, Nishiyama A. Rahman A, et al. Hypertens Res. 2017 Jun;40(6):535-540. doi: 10.1038/hr.2016.193. Epub 2017 Jan 19. Hypertens Res. 2017. PMID: 28100918 Review.
SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.
Piperidou A, Loutradis C, Sarafidis P. Piperidou A, et al. J Hum Hypertens. 2021 Jan;35(1):12-25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10. J Hum Hypertens. 2021. PMID: 32778748 Review.

References

1. Hypertens Res. 2015 Jun;38(6):367-74 - PubMed
1. Kidney Int. 2003 Jan;63(1):225-32 - PubMed
1. Clin Exp Hypertens. 2009 May;31(3):259-70 - PubMed
1. Diabetes Care. 2012 Jun;35(6):1364-79 - PubMed
1. Kidney Int. 2013 Mar;83(3):517-23 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information